JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Search

Ionis Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

75.28 0.75

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

74.82

Max

76.02

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-100M

-229M

Pardavimai

46M

203M

Pelno marža

-112.808

Darbuotojai

1,402

EBITDA

4.7B

4.6B

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+40.28% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-07-29

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-1.8B

12B

Ankstesnė atidarymo kaina

74.53

Ankstesnė uždarymo kaina

75.28

Naujienos nuotaikos

By Acuity

21%

79%

41 / 347 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

Ionis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-01 21:36; UTC

Įsigijimai, susijungimai, perėmimai

FTC Requires 365 Retail Markets to Divest Micromarket Kiosk Business to Clear Acquisition of Cantaloupe

2026-05-01 20:40; UTC

Įsigijimai, susijungimai, perėmimai

Meta Platforms Acquires Humanoid Robot Startup Assured Robot Intelligence

2026-05-01 18:37; UTC

Pagrindinės rinkos jėgos

Senseonic Shares Slide on Underwritten Offering Price

2026-05-01 16:46; UTC

Pagrindinės rinkos jėgos

Stellantis, Ferrari Fall on Trump Plan to Increase Tariff on European Cars, Trucks

2026-05-02 19:57; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire CEO Greg Abel Takes the Stage, Making a Case for the Post-Buffett Era -- 3rd Update

2026-05-02 15:24; UTC

Uždarbis

Berkshire CEO Greg Abel Takes the Stage, Talks Through Quarterly Results -- Update

2026-05-02 12:46; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Berkshire Profits More Than Double on Gains in Insurance, Railroad, Energy Businesses -- WSJ

2026-05-02 08:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-05-01 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-05-01 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-01 20:42; UTC

Uždarbis

Western Digital Beats Earnings Estimates. The Stock Is Falling Anyway. -- Barrons.com

2026-05-01 19:33; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-01 19:33; UTC

Rinkos pokalbiai

Change in Fed Leadership May Hamper Crypto Rebound -- Market Talk

2026-05-01 19:18; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Oil Rises for Second Consecutive Week Amid Middle East Standoff -- Market Talk

2026-05-01 19:13; UTC

Rinkos pokalbiai

Natural Gas Rises as Markets Wait for Warmer Temperatures -- Market Talk

2026-05-01 18:36; UTC

Uždarbis

3 Takeaways From Apple Earnings. The Stock Is Surging. -- Barrons.com

2026-05-01 18:35; UTC

Uždarbis

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

2026-05-01 18:28; UTC

Uždarbis

These Stocks Are Today's Movers: Apple, Sandisk, Roblox, Intel, Ferrari, Atlassian, Western Digital, Clorox, Paramount Skydance, and More -- Barrons.com

2026-05-01 18:27; UTC

Rinkos pokalbiai

Gold and Silver Higher for the Day, Lower For The Week -- Market Talk

2026-05-01 18:14; UTC

Įsigijimai, susijungimai, perėmimai

Barclays Completes Acquisition of Best Egg

2026-05-01 18:04; UTC

Uždarbis

The First $6 Trillion Company May Not Be Nvidia -- Barrons.com

2026-05-01 17:43; UTC

Rinkos pokalbiai

Home Sales in San Francisco Jump 22.2% in March -- Market Talk

2026-05-01 17:37; UTC

Rinkos pokalbiai

Crypto 'Fear and Greed Index' Returns to Neutral Reading After Brief Dip -- Market Talk

2026-05-01 17:30; UTC

Rinkos pokalbiai
Uždarbis

Apple's 2Q Print, 3Q Guide Set Up Stock to Outperform -- Market Talk

2026-05-01 17:28; UTC

Rinkos pokalbiai
Uždarbis

Apple's Shift From Net Cash Neutral Goal Seen as Cryptic Signal -- Market Talk

2026-05-01 17:21; UTC

Rinkos pokalbiai
Uždarbis

Apple Seen Absorbing Higher Memory Costs -- Market Talk

2026-05-01 17:19; UTC

Rinkos pokalbiai
Svarbiausios naujienos

U.S. Oil Rig Count Rises by 1 to 408 -- Market Talk

2026-05-01 16:38; UTC

Rinkos pokalbiai

Institutional Markets Begin to Trade on Event Contracts -- Market Talk

2026-05-01 16:23; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Skydance Gets a Double Upgrade. It's the Warner Bros. Deal. -- Barrons.com

2026-05-01 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Ionis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

40.28% į viršų

12 mėnesių prognozė

Vidutinis 105.6 USD  40.28%

Aukščiausias 130 USD

Žemiausias 72 USD

Remiantis 17 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ionis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

17 ratings

15

Pirkti

2

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

29.78 / 33.645Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Neutral Evidence

Vidutinės trukmės periodas

Very Strong Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

41 / 347 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat